semaglutide for weight loss in non diabetics #oralsemaglutide #weightloss #nondiabetics #morphhealthwellness #glp1weightlosstherapy #semaglutidetablets #tesofensinepeptide #noneedles #oralsemaglutide #nohiddenfees… Semaglutide for Non-Diabetic Weight Loss:

At 24 weeks, the mean percentage decrease in weight ranged from 7.2% to 17.5% across retatrutide groups versus 1.6% with placebo

These projections assume consistent daily dosing at 300-500 mcg subcutaneous, caloric deficit of 300-500 calories per day, and regular physical activity

The process works like this: you complete an online intake questionnaire covering your health history, current medications, and weight loss goals

In a body composition substudy in people with type 2 diabetes and obesity (PMID: 40609566), retatrutide produced a lean mass loss of about 38% of total weight loss, which falls within the 2040% range reported for other GLP1based therapies such as semaglutide and tirzepatide (see PMID: 40609564

Peptides like BPC-157 target tissue repair rather than symptom masking